Drug Profile
Research programme: liver X receptor beta agonists - Novartis
Latest Information Update: 13 Jul 2010
Price :
$50
*
At a glance
- Originator Novartis
- Class
- Mechanism of Action Liver X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Cardiovascular disorders; Diabetes mellitus; Inflammation
Most Recent Events
- 13 Jul 2010 Discontinued - Preclinical for Atherosclerosis in USA (unspecified route)
- 13 Jul 2010 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 13 Jul 2010 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route)